GJA1 and neoplasm: Regarding the clinical relevance of these findings, we observed that among the 14 patients with aberrant Cx43 immunostaining localization, four out of six patients (66.7%) harboring Cx43 gene mutations presented with advanced tumor stages (IIIa or IIIb).